LABA: Oral Corticosteroids: Predinsone Immunomodulators: SABA: alBUTEROL, levALBUTEROL, PirBUTEROL
Explanation
Asthma classifications and treatment
For a patient with intermittent asthma, the most appropriate treatment would be a short acting beta agonist, such as alBUTEROL. Fluticasone, Budesonide (not listed), and triacinolone are inhaled corticosteroids (ICS) and are given for patients with mild -severe persistent asthma (dose increases with severity) Salmeterol is a Long Acting Beta Agonist which is combined with an ICS to treat moderate persistent asthma Omalizumab is an immunomodulator and should be considered in cases of severe persistent asthma
In a mild persistent case...Symptoms > 2 days/week (not daily), Nighttime awakenings occur 3-4x/month, they use SABA Albuterol inhalers > 2days/week (not daily). Interference with activity is Minor. The FEV1 > 80%, and FEV1/FVC > normal. Exacerbations > 2 in a year
This patient has mild persistent asthma, he should follow step 2 treatment which is a low dose ICS. a LABA cannot be prescribed on it's own, it must be in conjunction with an inhaled corticosteroid. A SABA would be used in a patient who has intermittent asthma, nor mild persistent.
There are three options for moderate persistent asthma: low dose ICS +LABA, medium dose ICS, or Medium dose ICS +LABA. LABAs include Salmeterol, ICSs include Fluticasone, Budesonide, and triacinolone Albuterol is a short acting beta agonist that is used for patients with intermittent asthma Omalizumab is an immunomodulator and should be considered in cases of severe persistent asthma
For patients with severe persistent asthma: High dose ICS + LABA + (oral corticosteroid if severe enough), Consider omalizumab For intermittent: SABA (albuterol) For mild persistent: Low Dose ICS For Moderate: ICS + LABA or medium ICS,
Omalizumab is an immunomodulator and should be considered with severe persistent asthma